Letter to the EditorFull Access
Published Online:1 Jun 2001https://doi.org/10.1176/appi.ajp.158.6.968-a
- Cited by
- 12 August 2021 | Neuropsychopharmacology Reports, Vol. 41, No. 3
- World Journal of Clinical Cases, Vol. 9, No. 20
- 1 September 2016 | Acta Psychiatrica Scandinavica, Vol. 134, No. 5
- 23 March 2015 | Journal of Hospital Medicine, Vol. 10, No. 8
- 22 May 2015 | Pharmacology, Vol. 95, No. 5-6
- 31 August 2013 | Australasian Psychiatry, Vol. 22, No. 1
- 16 May 2011 | Therapeutic Advances in Psychopharmacology, Vol. 1, No. 2
- Journal of Clinical Psychopharmacology, Vol. 30, No. 6
- Journal of Psychiatric Practice, Vol. 16, No. 2
- 1 July 2007 | The Canadian Journal of Psychiatry, Vol. 52, No. 7
- 6 September 2012 | Obesity, Vol. 14, No. 1
- ULRICH SACHSSE,
M.D. , - SUSANNE VON DER HEYDE,
M.D. , and - GERALD HUETHER,
PH.D. ,
1 April 2002 | American Journal of Psychiatry, Vol. 159, No. 4- ULRICH SACHSSE,
- HARPREET S. DUGGAL,
M.B.B.S., D.P.M. , and - JOSEPH FETCHKO,
M.D. ,
1 April 2002 | American Journal of Psychiatry, Vol. 159, No. 4- HARPREET S. DUGGAL,
- RICHARD C. MILLSON,
M.D. , - JAMES A. OWEN,
PH.D. , - GUNTER W. LORBERG,
M.D. , and - LIANE TACKABERRY,
B.A. ,
1 April 2002 | American Journal of Psychiatry, Vol. 159, No. 4- RICHARD C. MILLSON,
- PAMELA D. BUTLER,
PH.D. , - ISAAC SCHECHTER,
PSY.D. , - VANCE ZEMON,
PH.D. , - STEPHEN G. SCHWARTZ,
M.D. , - VIVIENNE C. GREENSTEIN,
PH.D. , - JAMES GORDON,
PH.D. , - CHARLES E. SCHROEDER,
PH.D. , and - DANIEL C. JAVITT,
M.D., PH.D. ,
1 April 2002 | American Journal of Psychiatry, Vol. 159, No. 4- PAMELA D. BUTLER,
- 13 March 2002 | Pharmacoepidemiology and Drug Safety, Vol. 10, No. 7